Lab launches Canada’s first mail-in semen analysis kit
January 15, 2026
FlowLabs was recently featured on CP24 for the launch of its new discreet, mail-in semen analysis kit, designed to improve access to male fertility testing for patients across Canada.
The CP24 coverage highlights a long-standing challenge in fertility care: while semen analysis is often the first and most essential diagnostic step for couples beginning fertility investigations, many patients still face major logistical barriers to completing this testing—especially when they live far from qualified labs, have limited appointment availability, or experience discomfort with in-clinic collection.
Dr. Keith Jarvi, head of urology at Mount Sinai Hospital and director of the Murray Koffler Urologic Wellness Centre, emphasized why removing delays matters. In the CP24 feature, he underscored the central role semen analysis plays in fertility assessment and how access challenges can stall care at a critical moment.
To help close that gap, FlowLabs’ engineering team developed a mail-in kit that supports lab-quality semen analysis from home—allowing patients to collect their sample privately and ship it to FlowLabs laboratories for timely processing. The kit measures key indicators such as sperm count and motility, with the aim of delivering results comparable to traditional in-lab testing while reducing barriers tied to geography and wait times.
As FlowLabs noted in its materials, the impact is straightforward: faster access to testing can mean quicker results and fewer logistical hurdles for patients and their partners.
Dr. Jarvi also captured the intent behind the service in a single idea:
FlowLabs was recently featured on CP24 for the launch of its new discreet, mail-in semen analysis kit, designed to improve access to male fertility testing for patients across Canada.
The CP24 coverage highlights a long-standing challenge in fertility care: while semen analysis is often the first and most essential diagnostic step for couples beginning fertility investigations, many patients still face major logistical barriers to completing this testing—especially when they live far from qualified labs, have limited appointment availability, or experience discomfort with in-clinic collection.
Dr. Keith Jarvi, head of urology at Mount Sinai Hospital and director of the Murray Koffler Urologic Wellness Centre, emphasized why removing delays matters. In the CP24 feature, he underscored the central role semen analysis plays in fertility assessment and how access challenges can stall care at a critical moment.
To help close that gap, FlowLabs’ engineering team developed a mail-in kit that supports lab-quality semen analysis from home—allowing patients to collect their sample privately and ship it to FlowLabs laboratories for timely processing. The kit measures key indicators such as sperm count and motility, with the aim of delivering results comparable to traditional in-lab testing while reducing barriers tied to geography and wait times.
As FlowLabs noted in its materials, the impact is straightforward: faster access to testing can mean quicker results and fewer logistical hurdles for patients and their partners.
Dr. Jarvi also captured the intent behind the service in a single idea:
“This is trying to take the lab to the patients, as opposed to the patients to the lab.”
We’re proud to see CP24 recognizing this step forward in male fertility diagnostics—and the role accessible testing can play in helping couples make earlier, more informed decisions.